EyePoint Pharmaceuticals(DE:PV3B)
€0.25-0.03 (-9.35%)
DE:PV3B
EyePoint Pharmaceuticals ownership
€0.25
At close:-0.03 (-9.35%)
EyePoint Pharmaceuticals (PV3B) Ownership - Who Owns EyePoint Pharmaceuticals?
1 Followers
EyePoint Pharmaceuticals (PV3B) Ownership Overview
- 7.94% Insiders
- 14.18% Mutual Funds
- 38.36% Other Institutional Investors
- 10.31% ETFs
- 29.20% Public Companies and Individual Investors
The ownership structure of EyePoint Pharmaceuticals (DE:PV3B) stock is a mix of institutional, retail, and individual investors. Approximately 62.86% of the company’s stock is owned by Institutional Investors, 7.94% is owned by Insiders, and 29.20% is owned by Public Companies and Individual Investors.
Institutional holdings as of
The ownership structure of EyePoint Pharmaceuticals (DE:PV3B) stock is a mix of institutional, retail, and individual investors. Approximately 62.86% of the company’s stock is owned by Institutional Investors, 7.94% is owned by Insiders, and 29.20% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
| Date | Name | Activity | Value |
|---|---|---|---|
| Aug 17, 2026 | Karen Zaderej | $52,258 | |
| Jul 01, 2026 | Ramiro Ribeiro | $73,149 | |
| Apr 19, 2026 | Ramiro Ribeiro | $36,555 | |
| Mar 15, 2026 | Jay Duker | $19,710 |
Recent Hedge Fund Trading Activity
| Date | Firm | Activity | Value |
|---|---|---|---|
| Dec 31, 2025 | Woodline Partners Lp | €1,835,459 |
Top Shareholders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Cormorant Asset Management, Llc | 8,265,000 | Insider | 7.26% | 2,281,140 |
| BlackRock, Inc. | 7,982,162 | Institution | 7.02% | 2,203,077 |
| Federated Hermes Equity Funds | 4,760,141 | Institution | 4.18% | 1,313,799 |
| Ishares | 4,528,681 | Institution | 3.98% | 1,249,916 |
| Vanguard | 3,777,666 | Institution | 3.32% | 1,042,636 |
| Vanguard Index Funds | 3,539,772 | Institution | 3.11% | 976,977 |
| Franklin Strategic Series | 2,207,989 | Institution | 1.94% | 609,405 |
| Spdr | 1,444,274 | Institution | 1.27% | 398,620 |
| Mutual Fund Series Trust | 1,245,583 | Institution | 1.09% | 343,781 |
| Fidelity Salem Street Trust | 937,199 | Institution | 0.82% | 258,667 |
Top Mutual Fund Holders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Federated Hermes Equity Funds | 4,760,141 | Institution | 4.18% | 1,313,799 |
| Vanguard Index Funds | 3,539,772 | Institution | 3.11% | 976,977 |
| Franklin Strategic Series | 2,207,989 | Institution | 1.94% | 609,405 |
| Mutual Fund Series Trust | 1,245,583 | Institution | 1.09% | 343,781 |
| Fidelity Salem Street Trust | 937,199 | Institution | 0.82% | 258,667 |
| Fidelity Concord Street Trust | 785,131 | Institution | 0.69% | 216,696 |
| Federated Hermes Mdt Series | 621,538 | Institution | 0.55% | 171,544 |
| Vanguard Scottsdale Funds | 531,109 | Institution | 0.47% | 146,586 |
| Dfa Investment Dimensions Group Inc | 393,027 | Institution | 0.35% | 108,475 |
| Tiaa-cref Funds | 242,353 | Institution | 0.21% | 66,889 |
FAQ
Who Owns EyePoint Pharmaceuticals (DE:PV3B)?
According to the latest TipRanks data (13F holdings as of December 31, 2025), approximately 62.86% of the company's stock is held by institutional investors, 7.94% is held by insiders, and 29.20% is held by public companies and individual investors.
What percentage of EyePoint Pharmaceuticals (DE:PV3B) stock is held by institutional investors?
According to the latest TipRanks data (13F holdings as of December 31, 2025), approximately 62.86% of EyePoint Pharmaceuticals (DE:PV3B) stock is held by institutional investors: 14.18% by mutual funds, 10.31% by ETFs and 38.36% by other institutional investors.
What percentage of EyePoint Pharmaceuticals (DE:PV3B) stock is held by retail investors?
According to the latest TipRanks data (13F holdings as of December 31, 2025), approximately 29.20% of EyePoint Pharmaceuticals (DE:PV3B) stock is held by public companies and individual investors.
Who owns the most shares of EyePoint Pharmaceuticals (DE:PV3B)?
Cormorant Asset Management, LLC owns the most shares of EyePoint Pharmaceuticals (DE:PV3B).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.

